This increased expression of CXCL10 was also found in D3 lysates in the BBB model with PBMCs from control patients (by 191.10-fold) and mild AD patients (by 235.1-fold) compared to D3 lysates in BBB models without PBMCs (Table 2). Here, CXCL10 is linked to Alzheimer disease.